New study tests antacid for Post-PPI acid rebound relief

NCT ID NCT07291700

Recruiting now Symptom relief Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This observational study in Germany looks at whether hydrotalcite (Talcid) can ease acid-related symptoms like heartburn that occur when people stop long-term use of proton pump inhibitors (PPIs). About 167 adults who recently stopped PPIs will take hydrotalcite as needed for four weeks and report their symptom relief and satisfaction. The goal is to see if this antacid helps people avoid restarting PPIs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydrotalcite (Talcid chewable tablet)
What this could lead to: If successful, this could show that hydrotalcite is an effective on-demand option for managing acid rebound symptoms after stopping PPIs, helping people avoid restarting long-term acid suppression.
What could go wrong: This is a small observational study (167 participants) with no control group, so results may not prove cause and effect. The 40% dropout rate could also limit the reliability of findings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL REFLUX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease Heartburn Nausea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL REFLUX

Contacts and locations

Locations

Bayer Germany
NOT_YET_RECRUITING

Wuppertal, 42096, Germany
Bayer Vital GmbH
RECRUITING

Leverkusen, 51373, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.